A detailed history of Bank Of America Corp transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 179,912 shares of VERA stock, worth $6.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
179,912
Previous 200,152 10.11%
Holding current value
$6.75 Million
Previous $8.63 Million 24.58%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$33.72 - $48.82 $682,492 - $988,116
-20,240 Reduced 10.11%
179,912 $6.51 Million
Q1 2024

May 15, 2024

BUY
$14.91 - $49.14 $2.41 Million - $7.94 Million
161,669 Added 420.1%
200,152 $8.63 Million
Q4 2023

Feb 14, 2024

BUY
$9.29 - $16.0 $258,484 - $445,184
27,824 Added 261.04%
38,483 $591,000
Q2 2023

Aug 14, 2023

SELL
$6.11 - $17.83 $471,557 - $1.38 Million
-77,178 Reduced 87.87%
10,659 $171,000
Q1 2023

May 12, 2023

BUY
$5.41 - $18.3 $195,631 - $661,746
36,161 Added 69.98%
87,837 $681,000
Q4 2022

Feb 10, 2023

BUY
$15.74 - $22.19 $271,971 - $383,421
17,279 Added 50.23%
51,676 $999,000
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $171,753 - $288,758
12,943 Added 60.33%
34,397 $733,000
Q2 2022

Aug 12, 2022

BUY
$12.82 - $23.4 $74,997 - $136,890
5,850 Added 37.49%
21,454 $291,000
Q1 2022

May 16, 2022

BUY
$17.8 - $28.06 $65,806 - $103,737
3,697 Added 31.05%
15,604 $367,000
Q4 2021

Feb 08, 2022

BUY
$15.01 - $35.8 $80,843 - $192,818
5,386 Added 82.59%
11,907 $318,000
Q3 2021

Nov 15, 2021

BUY
$13.71 - $30.6 $4,236 - $9,455
309 Added 4.97%
6,521 $113,000
Q2 2021

Sep 13, 2021

BUY
$11.5 - $19.97 $71,438 - $124,053
6,212 New
6,212 $82,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.01B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.